Lilly's dulaglutide meets Phase III endpoints

Eli Lilly and Co. (NYSE:LLY) said once-weekly dulaglutide met the primary endpoints in three Phase III trials to treat Type II diabetes. In 978 diabetics on metformin and pioglitazone in the AWARD-1 trial, dulaglutide significantly reduced HbA1c from baseline to week 26 vs. placebo, and significantly reduced HbA1c from baseline to week 26 vs. active control Byetta exenatide from Amylin Pharmaceuticals Inc.

In 807 patients with early diabetes in the AWARD-3 trial, dulaglutide was non-inferior and superior to metformin in reducing HbA1c from baseline to week 26. In 1,098 diabetics on metformin in the AWARD-5 trial, dulaglutide was non-inferior and superior to Januvia sitagliptin in reducing HbA1c from baseline to week 52. ...